These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20859201)

  • 41. Clinical experience with recombinant pollen allergens.
    Cromwell O
    Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):245-6. PubMed ID: 17124784
    [No Abstract]   [Full Text] [Related]  

  • 42. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma.
    Nasser S; Vestenbaek U; Beriot-Mathiot A; Poulsen PB
    Allergy; 2008 Dec; 63(12):1624-9. PubMed ID: 19032235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Component-resolved diagnosis for phleum allergy: the role of recombinants.
    De Amici M; Alesina R; Moratti R; Ciprandi G
    J Asthma; 2010 Sep; 47(7):750-3. PubMed ID: 20726834
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel strategies for the development of a vaccine for Parietaria allergy.
    Bonura A; Colombo P
    Int J Immunopathol Pharmacol; 2011; 24(2):297-304. PubMed ID: 21658304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives.
    Pauli G; Purohit A; Oster JP; de Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
    Int Arch Allergy Immunol; 1999; 118(2-4):216-7. PubMed ID: 10224385
    [No Abstract]   [Full Text] [Related]  

  • 46. Heterogeneity of commercial timothy grass pollen extracts.
    Focke M; Marth K; Flicker S; Valenta R
    Clin Exp Allergy; 2008 Aug; 38(8):1400-8. PubMed ID: 18564332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current status of subcutaneous and sublingual immunotherapy with recombinant allergens.
    Jutel M; Solarewicz-Madejek K; Smolinska S
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2013; 97():133-9. PubMed ID: 24912327
    [No Abstract]   [Full Text] [Related]  

  • 48. [New administration routes for immunotherapy].
    Martorell Aragonés A
    Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apple desensitization in two patients with PR-10 proteins allergy.
    Nucera E; Aruanno A; Lombardo C; Patriarca G; Schiavino D
    Allergy; 2010 Aug; 65(8):1060-1. PubMed ID: 19958318
    [No Abstract]   [Full Text] [Related]  

  • 50. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subcutaneous injection immunotherapy for optimal effectiveness.
    Nelson HS
    Immunol Allergy Clin North Am; 2011 May; 31(2):211-26, viii. PubMed ID: 21530815
    [TBL] [Abstract][Full Text] [Related]  

  • 52. State-of-the-art allergoids: overview of clinical trials.
    Rak S
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():106-9; discussion 109-11. PubMed ID: 20799450
    [No Abstract]   [Full Text] [Related]  

  • 53. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy.
    Pipet A; Botturi K; Pinot D; Vervloet D; Magnan A
    Respir Med; 2009 Jun; 103(6):800-12. PubMed ID: 19216064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dusting off recombinant allergens.
    Marshall GD; Davis F
    Nat Biotechnol; 1997 Aug; 15(8):718-9. PubMed ID: 9255778
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The value of immunotherapy in treatment of IgE-induced allergic diseases].
    Müller UR
    Ther Umsch; 1994 Jan; 51(1):67-76. PubMed ID: 7511841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiallergen immunotherapy for allergic rhinitis and asthma.
    Nelson HS
    J Allergy Clin Immunol; 2009 Apr; 123(4):763-9. PubMed ID: 19217653
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy].
    Ibáñez Sendín MD
    Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What will allergen immunotherapy look like in the future?
    Nelson HS
    Ann Allergy Asthma Immunol; 2012 Aug; 109(2):87-9. PubMed ID: 22840246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.